Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zirconium-89-labeled RO5479599 is a radiolabeled monoclonal antibody designed for immunoPET imaging. The antibody targets HER3 (human epidermal growth factor receptor 3), which is overexpressed in various solid tumors. By labeling the antibody with the positron-emitting radioisotope zirconium-89, this agent enables non-invasive visualization and quantification of HER3 expression in tumors using PET imaging. This approach supports patient selection and monitoring of therapeutic response in clinical trials involving anti-HER3 therapies. The primary indication studied has been metastatic and/or locally advanced malignant HER3-positive solid tumors of epithelial cell origin[2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zirconium-89-labeled RO5479599.